Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease
Mengya Wang, Huayuan Liu, Zegang Ma
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 23

Showing 23 citing articles:

Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation
Berhanu Geresu Kibret, Ana Canseco-Alba, Emmanuel S. Onaivi, et al.
Frontiers in Behavioral Neuroscience (2023) Vol. 17
Open Access | Times Cited: 14
Neuroplasticity in levodopa-induced dyskinesias: An overview on pathophysiology and therapeutic targets
Francesco Bove, Benedetta Angeloni, Pasquale Sanginario, et al.
Progress in Neurobiology (2023) Vol. 232, pp. 102548-102548
Closed Access | Times Cited: 11
Potential Neuroprotective Effect of the Endocannabinoid System on Parkinson’s Disease
María Fernanda Urmeneta-Ortíz, Aldo Rafael Tejeda-Martínez, Orfil González‐Reynoso, et al.
Parkinson s Disease (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 4
JWH133 attenuates behavior deficits and iron accumulation in the 6-OHDA-induced Parkinson's disease model rats
Man Liu, Dong Pan, MengYa Wang, et al.
Journal of Neurophysiology (2024) Vol. 132, Iss. 3, pp. 733-743
Closed Access | Times Cited: 3
Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential
Barbara Vuić, Tina Milos, Lucija Tudor, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3000-3000
Open Access | Times Cited: 15
Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson’s Disease
Efthalia Angelopoulou, Anastasia Bougea, Yam Nath Paudel, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1138-1138
Open Access | Times Cited: 7
Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders
Kanchan Bala, Pratyush Porel, Khadga Raj Aran
Psychopharmacology (2024)
Closed Access | Times Cited: 2
Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review
Panteleimon Oikonomou, Wolfgang H. Jost
Journal of Neural Transmission (2022) Vol. 129, Iss. 10, pp. 1247-1256
Closed Access | Times Cited: 9
The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases
Ivona Maria Tudorancea, Mitică Ciorpac, Gabriela Dumitrița Stanciu, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2492-2492
Open Access | Times Cited: 8
The Role of Cannabinoid Type 2 Receptors in Parkinson’s Disease
Maria Sofia Basile, Emanuela Mazzon
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2986-2986
Open Access | Times Cited: 8
A single-center real-life study on the use of medical cannabis in patients with dystonia
Saar Anis, Achinoam Faust‐Socher, Diana Sverdlov, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 4
Outcomes and Outlooks of Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson's Disease
Л. Г. Хаспеков, С. Н. Иллариошкин
(2024)
Open Access | Times Cited: 1
Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson’s Disease
Л. Г. Хаспеков, С. Н. Иллариошкин
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8520-8520
Open Access | Times Cited: 1
GPCR-Mediated Natural Products and Compounds: Potential Therapeutic Targets for the Treatment of Neurological Diseases
Xing Xia Wang, Xiang Ji, Jing‐Jer Lin, et al.
Pharmacological Research (2024) Vol. 208, pp. 107395-107395
Open Access | Times Cited: 1
Pharmacotherapy for the core symptoms of autism spectrum disorder
Peiwen Tan, X. Y. Shen, Lizhang Zeng, et al.
Journal of Zhejiang University SCIENCE B (2024) Vol. 25, Iss. 11, pp. 956-971
Closed Access | Times Cited: 1
Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review
Gidion Wilson, Lingling Yang, Xiaojuan Su, et al.
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1410-1444
Closed Access | Times Cited: 3
Treadmill exercise modulates nigral and hippocampal cannabinoid receptor type 1 in the 6-OHDA model of Parkinson’s disease
Karina Henrique Binda, Anne M. Landau, Marucia Chacur, et al.
Brain Research (2023) Vol. 1814, pp. 148436-148436
Open Access | Times Cited: 2
Using caffeine as a chemical means to induce flow states
Niklas Reich, Michael V. Mannino, Steven Kotler
Neuroscience & Biobehavioral Reviews (2024) Vol. 159, pp. 105577-105577
Open Access
Beyond dopamine: exploring endocannabinoids in Parkinson’s disease
Disa Basu, Nannan Yang, Jinhui Ding, et al.
Ageing and Neurodegenerative Diseases (2024) Vol. 4, Iss. 3
Open Access
Modeling Neural Circuits in Parkinson’s Disease
Ganna Ameen, Basant Mohamed Osama
(2024), pp. 511-547
Closed Access
Commentary: Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease
Panteleimon Oikonomou, Wolfgang H. Jost
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 2
Fatty acid amide hydrolase, anandamide, and neurological diseases
Filomena Fezza, Emanuele Criscuolo, Maria Laura De Sciscio, et al.
Elsevier eBooks (2023), pp. 417-428
Closed Access
Modeling Neural Circuits in Parkinson’s Disease
Ganna Ameen, Basant Mohamed Osama
(2023), pp. 1-37
Closed Access
Page 1

Scroll to top